The history of antibody engineering and production in drug discovery can be traced back to the 1970s and 1980s [1] when scientists first began to explore the potential of using antibodies as ...

In the past few years, multispecific antibodies, such as trispecific, bispecific, and tetraspecific, have become popular in antibody therapeutics. Compared to conventional monospecific antibodies, ...

Antibody humanization involves modifying antibodies from non-human sources, such as mice, to decrease their immunogenicity in human applications. While mouse monoclonal antibodies are specific, they ...

An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how antibody medicines are tested and brought to patients. The work, published ...

Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 ...

The global antibody discovery market, valued at USD 11.15 billion in 2025, is expected to surge to USD 35.35 billion by 2035, growing at a CAGR of 12.23%. This growth is fueled by advancements in ...

Antibody production companies are essential in dealing with the growing demand for antibodies for life sciences, therapeutic, and diagnostic applications. Therefore, a number of service providers are ...

Assessing therapeutic window and dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody): Integrating nonclinical and clinical data using mathematical modeling. This is an ASCO Meeting Abstract from ...

A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+ early and ...